Monitored issues and legislation related to the 340(b) program.
H.R.5801: HELP Copays Act.
Medicare Implementation of the Inflation Reduction Act.
Duration: February 1, 2013
to
present
General Issues: Health Issues , Medicare/Medicaid , Pharmacy , Budget/Appropriations , Natural Resources , Copyright/Patent/Trademark , Taxation/Internal Revenue Code
Spending: about $2,230,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2013: House of Representatives, U.S. Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Darren Willcox
Asst. for Policy, Speaker Dennis Hastert
Admin Asst; Leg Dir; Leg Asst, Congressman Porter Goss
House Rules Comm Assoc, Subcommittee Staff Direction
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on April 22.
Original Filing: 301575583.xml
Lobbying Issues
Monitored issues and legislation related to the 340(b) program.
H.R.5801: HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Implementation of the Inflation Reduction Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2023
In Q4, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Jan. 18.
Original Filing: 301529193.xml
Lobbying Issues
Monitored issues and legislation related to the 340(b) program.
H.R.5801: HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Implementation of the Inflation Reduction Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2023
In Q3, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Oct. 20, 2023.
Original Filing: 301511879.xml
Lobbying Issues
Monitored issues and legislation related to the 340(b) program.
H.R.5801: HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Implementation of the Inflation Reduction Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
In Q2, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on July 20, 2023.
Original Filing: 301489615.xml
Lobbying Issues
Monitored issues and legislation related to the 340(b) program.
H.R.830: HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Implementation of the Inflation Reduction Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on April 20, 2023.
Original Filing: 301467236.xml
Lobbying Issues
Monitored issues and legislation related to the 340(b) program.
H.R.830: HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Implementation of the Inflation Reduction Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Jan. 19, 2023.
Original Filing: 301435743.xml
Lobbying Issues
Monitored issues and legislation related to the 340(b) program.
H.R.5801 - HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413189.xml
Lobbying Issues
Monitored issues and legislation related to the 340(b) program.
H.R.5801: HELP Copays Act.
S.4348: FDASLA Act of 2022 and H.R.7667: Food and Drug Amendments of 2022.
H.R.5376 - Inflation Reduction Act of 2022.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2022
In Q2, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on July 20, 2022.
Original Filing: 301390345.xml
Lobbying Issues
Monitored issues and legislation related to the 340(b) program.
H.R.5801: HELP Copays Act.
S.4348: FDASLA Act of 2022 and H.R.7667: Food and Drug Amendments of 2022.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
In Q1, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on April 19, 2022.
Original Filing: 301363355.xml
Lobbying Issues
Monitored issues and legislation related to the 340(b) program.
H.R.5801: HELP Copays Act.
Reauthorization of the Prescription Drug User Fee Act and related issues.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2021
In Q4, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Jan. 20, 2022.
Original Filing: 301331667.xml
Lobbying Issues
Monitored issues and legislation related to 340(b) program.
H.R.5801: HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301313352.xml
Lobbying Issues
Monitored issues and legislation related to 340(b) program.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301289962.xml
Lobbying Issues
Education about the 340(b) drug discount program.
FY 2021 NBPP rule as it relates to copay accumulators.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to pharmaceutical intellectual property.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2021
In Q1, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on April 19, 2021.
Original Filing: 301258190.xml
Lobbying Issues
Education about the 340(b) drug discount program.
FY 2021 NBPP rule as it relates to copay accumulators.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301238607.xml
Lobbying Issues
Education about the 340(b) drug discount program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
CMS proposed rule on Medicaid Drug Rebate program.
H.R.133: Consolidated Appropriations Act, 2021 as it relates to health extenders.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2020
In Q3, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222629.xml
Lobbying Issues
Education about the 340(b) drug discount program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.7647: To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage.
FY 2021 Notice of Benefits and Payment Parameters proposed rule.
CMS proposed rule on Medicaid Drug Rebate program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2020
In Q2, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301201585.xml
Lobbying Issues
Education about the 340(b) drug discount program.
H.R.1425: Patient Protection and Affordable Care Enhancement Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2021 Notice of Benefits and Payment Parameters proposed rule.
CMS proposed rule on Medicaid Drug Rebate program.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2020
In Q1, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on April 20, 2020.
Original Filing: 301176656.xml
Lobbying Issues
Education about the 340(b) drug discount program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislative proposals to smooth out of pocket costs for patients in Medicare Part D.
FY 2021 Notice of Benefits and Payment Parameters proposed rule.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2019
In Q4, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Jan. 21, 2020.
Original Filing: 301128853.xml
Lobbying Issues
Education about the 340(b) drug discount program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about out of pocket costs for patients in Medicare Part D.
H.R.3: Lower Drug Costs Now Act of 2019.
H.R.19: Lower Costs, More Cures Act of 2019.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2019
In Q3, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Oct. 21, 2019.
Original Filing: 301078369.xml
Lobbying Issues
Education about the 340(b) drug discount program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Education about out of pocket costs for patients in Medicare Part D.
S.2543: Prescription Drug Pricing Reduction Act of 2019.
Regulatory and legislative proposals in the Administrations Rx Blueprint.
H.R.3: Lower Drug Costs Now Act of 2019.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2019
In Q2, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on July 22, 2019.
Original Filing: 301056756.xml
Lobbying Issues
Education about the 340(b) drug discount program.
H.R.2113: Prescription Drug STAR Act.
S. Lower Health Care Costs Act of 2019.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Education about out of pocket costs for patients in Medicare Part D.
Regulatory and legislative proposals in the Administrations Blueprint.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2019
In Q1, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on April 22, 2019.
Original Filing: 301035087.xml
Lobbying Issues
Education about the 340(b) drug discount program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.259: Medicaid Extenders Act of 2019.
Education about out of pocket costs for patients in Medicare Part D.
Education about CMS rule changing protections for beneficiaries in Medicare Part D six protected classes.
Regulatory and legislative proposals in the Administrations Blueprint.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2018
In Q4, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Jan. 22, 2019.
Original Filing: 301015880.xml
Lobbying Issues
Education about the 340(b) drug discount program.
H.R.4710: 340(b) PAUSE Act.
H.R.5598: 340B Optimization Act.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2018
In Q3, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Oct. 16, 2018.
Original Filing: 300985882.xml
Lobbying Issues
Education about the 340(b) drug discount program.
H.R.4710: 340(b) PAUSE Act.
H.R.5598: 340B Optimization Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.6642: "to sunset the limit on the maximum rebate amount for single source drugs".
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2018
In Q2, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on July 20, 2018.
Original Filing: 300975564.xml
Lobbying Issues
Education about the 340(b) drug discount program.
H.R.4710: 340(b) PAUSE Act.
H.R.5598: 340B Optimization Act.
Education about Endometriosis Awareness Month and the need for greater awareness of the disease.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2018
In Q1, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on April 19, 2018.
Original Filing: 300950240.xml
Lobbying Issues
Education about the 340(b) drug discount program.
H.R.4710: 340(b) PAUSE Act.
Education about Endometriosis Awareness Month and the need for greater awareness of the disease.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D donut hole provision and IPAB repeal.
H.R.1625: Consolidated Appropriations Act, 2018.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2017
In Q4, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Jan. 19, 2018.
Original Filing: 300929299.xml
Lobbying Issues
H.R.1703: Medical Product Communications Act of 2017.
Education about the 340(b) drug discount program.
H.R.3922: CHAMPIONING HEALTHY KIDS Act.
H.Res.403: Supporting the designation of March 2018 as Endometriosis Awareness Month.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2017
In Q3, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Oct. 20, 2017.
Original Filing: 300915507.xml
Lobbying Issues
H.R.1628: American Health Care Act and S. Better Care Reconciliation Act.
H.R.1703: Medical Product Communications Act of 2017.
H.R.2430/S.934: FDA Reauthorization Act of 2017.
Education about the 340(b) drug discount program.
Reauthorization of the Children's Health Insurance Program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2017
In Q2, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on July 18, 2017.
Original Filing: 300888090.xml
Lobbying Issues
H.R. 1628: American Health Care Act.
H.R.1703: Medical Product Communications Act of 2017.
Prescription Drug User Fee Act (PDUFA) Reauthorization.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2017
In Q1, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on April 21, 2017.
Original Filing: 300878588.xml
Lobbying Issues
H.R. 1628: H.R.1628 - American Health Care Act.
H.R. 749: Lower Drug Costs through Competition Act.
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2017 Budget Resolution (S. Con. Res. 3/H. Res. 48).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2016
In Q4, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Jan. 18, 2017.
Original Filing: 300848335.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
2016 CMS proposed rule implementing a new Part B drug payment model.
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 34: 21st Century Cures Act conference report.
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2016
In Q3, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Oct. 20, 2016.
Original Filing: 300834859.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
2016 CMS proposed rule implementing a new Part B drug payment model.
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
H.R. 6: 21st Century Cures Act.
H.R. 6174: Closing Loopholes for Orphan Drugs Act.
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2016
In Q2, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on July 19, 2016.
Original Filing: 300815083.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
2016 CMS proposed rule implementing a new Part B drug payment model.
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
H.R. 6: 21st Century Cures Act.
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2016
In Q1, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on April 20, 2016.
Original Filing: 300803027.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
March 2016 CMS proposed rule implementing a new Part B drug payment model.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
FY 2017 MILCON/VA appropriations as it relates to increased appropriations for Viral Hepatitis Testing for VA.
S. 524: Comprehensive Addiction and Recovery Act of 2016 as it relates to Rx take back programs.
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
H.R. 6: 21st Century Cures Act.
Education about the value of innovative new medicines.
Education about the 340(b) program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2015
In Q4, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Jan. 19, 2016.
Original Filing: 300776290.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
P.L. 114-113: "Consolidated Appropriations Act of 2015" as it relates to increased appropriations for Viral Hepatitis Testing for VA and reauthorization of the rare disease pediatric review voucher program.
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
H.R. 6: 21st Century Cures Act.
Education about the value of innovative new medicines.
Education about the 340(b) program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
P.L. 114-74: Bipartisan Budget Act of 2015.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2015
In Q3, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Oct. 20, 2015.
Original Filing: 300763506.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1101: Viral Hepatitis Testing Act.
Increased appropriations for Viral Hepatitis Testing for CDC and VA.
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars, including patent dispute resolution.
H.R. 6: 21st Century Cures Act, including inclusion of H.R. 971: OPEN Act.
Education about the value of innovative new medicines.
Education about the 340(b) program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 9: Innovation Act, including proposed changes to the Inter Partes Review (IPR) process at the Patent and Trademark Office (PTO).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2015
W Strategies, LLC amended a lobbying report for representation of AbbVie Inc. in Q32015 on Oct. 20, 2015.
Original Filing: 300763560.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1101: Viral Hepatitis Testing Act.
Increased appropriations for Viral Hepatitis Testing for CDC and VA.
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars, including patent dispute resolution.
H.R. 6: 21st Century Cures Act, including inclusion of H.R. 971: OPEN Act.
Education about the value of innovative new medicines.
Education about the 340(b) program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 9: Innovation Act, including proposed changes to the Inter Partes Review (IPR) process at the Patent and Trademark Office (PTO).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on July 20, 2015.
Original Filing: 300743431.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1101: Viral Hepatitis Testing Act.
Increased appropriations for Viral Hepatitis Testing for CDC and VA.
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars, including patent dispute resolution.
H.R. 6: 21st Century Cures Act, including inclusion of H.R. 971: OPEN Act.
Education about the value of innovative new medicines.
Education about the 340(b) program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 9: Innovation Act, including proposed changes to the Inter Partes Review (IPR) process at the Patent and Trademark Office (PTO).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2015
In Q1, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on April 17, 2015.
Original Filing: 300718801.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
H.R. 2: Medicare Access and CHIP Reauthorization Act of 2015.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1101: Viral Hepatitis Testing Act.
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars, including patent dispute resolution.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Education about the value of innovative new medicines.
Education about the 340(b) program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2014
In Q4, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Jan. 19, 2015.
Original Filing: 300700827.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3723: Viral Hepatitis Testing Act.
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Oct. 16, 2014.
Original Filing: 300684672.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3723: Viral Hepatitis Testing Act.
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
S. 2360/H.R. 4679: Stop Corporate Inversion Act of 2014.
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
In Q2, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on July 21, 2014.
Original Filing: 300666129.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3723: Viral Hepatitis Testing Act.
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).Education about the value of innovative new medicines.
Proposed changes to generic drug labeling.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
S. 2360/H.R. 4679: Stop Corporate Inversion Act of 2014.
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2014
In Q1, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on April 14, 2014.
Original Filing: 300635664.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
H.R. 4302: Protecting Access to Medicare Act of 2014.
H.R. 4160: Keep the Promise to Seniors Act of 2014.CMS proposed rule affecting the Medicare Advantage and Medicare Prescription Drug Benefit (Part D) Programs, specifically as it relates to changes to the Part D programs, including coverage of therapeutic classes and non interference.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3723: Viral Hepatitis Testing Act.
Implementation of Affordable Care Act as it relates to a regulatory pathway for biosimilars.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2013
In Q4, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Jan. 20, 2014.
Original Filing: 300626546.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
H.R. 2810, S.: Medicare Patient Access and Quality Improvement Act of 2013
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Education and outreach regarding proposed legislation to promote HCV testing.
Monitored implementation of Affordable Care Act as it relates to a regulatory for biosimilars.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 3309: Innovation Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.J. Res. 59 The Bipartisan Budget Act of 2013 Public Law No: 113-067.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2013
In Q3, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on Oct. 16, 2013.
Original Filing: 300601799.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
S. 957: Drug Supply Chain Security Act.
S. 959: Pharmaceutical Compounding Quality and Accountability Act.
H.R. 3089: Compounding Clarity Act of 2013.H.R. 3204: The Drug Quality and Security Act.
Education and outreach regarding proposed legislation to promote HCV testing.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2013
In Q2, W Strategies, LLC lobbied for AbbVie Inc. , earning $50,000. The report was filed on July 19, 2013.
Original Filing: 300577228.xml
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013.
S. 957: Drug Supply Chain Security Act.
S. 959: Pharmaceutical Compounding Quality and Accountability Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Monitored legislative efforts to reform the corporate tax system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
In Q1, W Strategies, LLC lobbied for AbbVie Inc. , earning $30,000. The report was filed on April 16, 2013.
Original Filing: 300558909.xml
Lobbying Issues
FY 2014 House and Senate Budget Resolutions as they relate to Medicare savings.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education and outreach about the competitive elements of the Medicare Part D drug benefit and opposition to legislation imposing Medicaid style manufacturer rebates in the program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
"Safe Prescribing Act of 2013".
Federal legislative efforts to enhance the security and integrity of the domestic pharmaceutical distribution system.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2013
W Strategies, LLC filed a lobbying registration on Feb. 24, 2013 to represent AbbVie Inc., effective Feb. 1, 2013.
Original Filing: 300545884.xml
Issue(s) they said they’d lobby about: Education and outreach about the Medicare Part D drug benefit.
Implementation of the Affordable Care Act.
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA). .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate